© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
The Damon Runyon Cancer Research Foundation awards $2.8 million to innovative early career scientists.
The National Cancer Institute discusses the progress of the Cancer Moonshot to accelerate cancer research.
Damon Runyon Cancer Research Foundation shares some exciting discoveries made by Damon Runyon researchers in 2020.
Study finds that using steroids to treat brain tumor symptoms may limit the effectiveness of immunotherapy drugs against these tumors.
Scientists assembled the largest molecular dataset and used it to uncover new details that may help in diagnosis and treatment.
Orgovyx (relugolix) may eliminate some patients’ need to visit a clinic for treatments administered by a health care provider.
Tagrisso (osimertinib) was approved for non-small cell lung cancer patients with EGFR-positive tumors.
Xpovio (selinexor) was approved for adults with multiple myeloma who have received at least one prior therapy.
Monoclonal antibody delays disease progression in people with previously treated HER2-positive tumors.
Mary Jo Rogers discusses her experience with cancer treatment after her 2011 diagnosis of Stage 3C melanoma.
Researchers have evidence that cholesterol-lowering drugs might offer a way to improve success rates of immunotherapy.
Researchers at the annual Society for the Immunotherapy for Cancer reported on melanoma clinical trial results from this year.
The stories behind three sculptures inspired by a Colorado sculptor’s cancer journey.
The nanoparticles led to more cancer-killing immune cells and slowed the growth of melanoma in mice.
Though I’ve had many truly amazing and exciting things happen this year, there’s still the stress of living in a divided country.
Damon Runyon researchers are making an impact through understanding the biology and developing novel treatments.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
